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Abstract 
Background: Implantable loop recorders (ILR) are a valuable tool for the investigation of unexplained 
syncopal episodes. The aim of this retrospective single center study was to identify predictive factors for 
pacemaker implantation in patients with unexplained syncope who underwent ILR insertion.
Methods: One hundred six patients were retrospectively analyzed (mean age 59.1 years; 47.2% male) 
with unexplained syncope and negative conventional testing who underwent ILR implantation. The pri-
mary study endpoint was detection of symptomatic or asymptomatic bradycardia requiring pacemaker 
implantation. 
Results: The average follow-up period after ILR implantation was 20 ± 15 months. Pacemaker im-
plantation according to current guidelines was necessary in 22 (20.8%) patients, mean duration until 
index bradycardia was 81 ± 88 (2–350) days. Ten (45.5%) patients received a pacemaker due to sinus 
arrest, 7 (31.8%) patients due to third-degree atrioventricular block, 2 (9.1%) patients due to second-
degree atrioventricular block and 1 (4.5%) patient due to atrial fibrillation with a slow ventricular rate. 
Three factors remained significant in multivariate analysis: obesity, which defined by a body mass index 
above 30 kg/m² (OR: 7.39, p = 0.014), a right bundle branch block (OR: 9.40, p = 0.023) and chronic 
renal failure as defined by a glomerular filtration rate of less than 60 mL/min (OR: 6.42, p = 0.035). 
Conclusions: Bradycardia is a frequent finding in patients undergoing ILR implantation due to un-
explained syncope. Obesity, right bundle branch block and chronic renal failure are independent clinical 
predictors of pacemaker implantation. (Cardiol J 2019; 26, 1: 36–46)
Key words: implantable loop recorder, unexplained syncope, pacemaker
Introduction
Syncope is common in the general population 
and is an important clinical problem with adverse 
outcomes from associated physical trauma, nega-
tive impact on life quality and increased cardiovas-
cular risk [1, 2]. In addition, the investigation of 
syncope imposes a significant economic burden on 
society [3]. With a cumulative lifetime incidence 
of about 40% [4], syncope accounts for 1–3% of 
emergency department visits [1]. 
To investigate the underlying cause of syn-
cope is often a difficult task, because underlying 
abnormalities are usually not present at the time 
of clinical evaluation. The European Society of 
Cardiology (ESC) guidelines for the diagnosis and 
management of syncope highlight the use of im-
plantable loop recorders (ILRs) by including ILRs in 
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class I recommendations for an evaluation of recur-
rent unexplained syncope, either in the early phase 
in non-high risk patients or after a comprehensive 
workup in high risk patients [5]. The ability of ILRs 
to continuously monitor cardiac rhythm over long 
periods makes them powerful diagnostic tools 
for patients with unexplained syncope [6]. Using 
ILRs, in the majority of patients a diagnosis can be 
established by performing long-term symptom — 
rhythm correlation [7–9]. Cardiac arrhythmias as 
primary cause of syncopes are common and most 
of them are caused by bradyarrhythmic events 
[10]. In cases of recurrent syncopal events due 
to bradyarrhythmia, pacemaker (PM) implanta-
tion significantly improves patient symptoms and 
prognosis [11]. Study data on possible predictive 
factors for bradycardia requiring PM implantation 
in patients with unexplained syncope receiving an 
ILR is limited [12, 13]. 
The aim of the present study was to identify 
clinical predictors of significant bradycardia requir-
ing PM implantation in patients who underwent 
ILR implantation due to unexplained syncope.
Methods
Study design 
The present study is a retrospective single 
center study, including patients who received an 
ILR due to unexplained syncope after conventional 
diagnostic work-up. A comprehensive review of 
patient charts was performed to identify possible 
clinical predictive factors for PM implantation due 
to bradyarrhythmias in the study population. The 
study protocol was approved by the human ethics 
committee of the Charité — Universitätsmedizin 
Berlin (ethic application number: EA1/234/14). All 
patients gave their written informed consent for 
scientific data analyses on a retrospective basis at 
hospital admission.
Study population
The study population included all consecutive 
patients referred to this institution (Department of 
Cardiology, University Hospital Charité) between 
February 2009 and August 2014, who underwent 
ILR implantation for further investigation of un-
explained syncope. The diagnostic algorithm prior 
to ILR implantation included clinical evaluation, 
a 12-lead surface electrocardiogram (ECG) and 
echocardiography and, if considered appropriate, 
coronary angiography or cardiac stress testing, 
Holter monitoring, invasive electrophysiology 
and cardiac magnetic resonance imaging (cMRI). 
Details on the extent of conventional and special 
diagnostic tests are outlined in Table 1A. Clini-
cal data for anamneses, features of the syncopal 
episodes, demographics, comorbidities, labora-
tory results, ECG parameters, echocardiographic 
findings and concomitant medical treatment were 
collected from the medical records stored on the 
hospital database (Tables 1A and 1B). Patients with 
coronary artery disease, valvular heart disease 
stage ≥ II, cardiomyopathy (HCM, DCM, ARVC), 
septum hypertrophy ≥ 14 mm or left ventricular 
ejection fraction (LVEF) < 55% were included un-
der the term ‘structural heart disease’. Moderate 
to severe structural heart disease was defined as 
valvular heart disease stage ≥ II or LVEF < 45%.
After hospital discharge all patients had rou-
tinely ILR interrogations at 4-month intervals 
at the documented outpatient clinic. In addition, 
patients had follow-up after each event suggestive 
for bradyarrhythmic or tachyarrythmic episodes to 
analyze stored ILR data.
ILR implantation
The ILR implantation in the present study 
population was performed by a cardiologist at this 
institution. At the time of implantation automatic 
activation was programmed to detect bradyar-
rhythmias (< 40 bpm) and tachyarrhythmias 
(> 170 bpm). Automatic algorithms for detection of 
atrial fibrillation (AF) were activated if available. The 
following types of ILR were used: 47 (44.3%) patients 
received a Reveal® DX 9528 (Medtronic, Minneapolis, 
MN, USA), 44 (41.5%) patients a Reveal® XT 9529 
(Medtronic, Minneapolis, MN, USA), 5 (4.7%) pa-
tients a ConfirmTM (St. Jude Medical, St. Paul, MN, 
USA) and 10 (9.4%) patients a BioMonitor (Biotronik, 
Berlin, Germany). Patients were instructed to acti-
vate the ILR manually in case of symptoms.
Study end points
Primary end point of this study was implanta-
tion of a PM due to documented bradyarryhthmic 
events. Within the ILR baseline detection setting 
bradyarrhythmic events were defined either by 
pauses of more than 3 s or by a heart rate of less 
than 40 bpm. Tachyarrhythmic episodes were 
defined as ventricular heart rate of more than 
170 bpm. Secondary endpoint included syncope 
recurrence, AF and flutter and ventricular tachy-
cardia after the index event.
PM implantation
Pacemaker implantation due to documented 
bradycardia was performed according to the ESC 
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Table 1A and B. Baseline demographic and clinical characteristics of the study population before  
insertion of an implantable loop recorder. 
Table 1A.
Parameter All patients  
(n = 106)
Patients with PM  
(n = 22) 
Patients without PM  
(n = 84)
P
Study population
Age [years] 59.12 ± 17.49 (21–89) 62.18 ± 12.68 (32–76) 58.32 ± 18.52 (21–89) 0.588
Age ≥ 75 years 19 (8.4%) 3 (13.6%) 16 (19.0%) 0.758
Male gender 50 (47.17%) 10 (45.5%) 40 (47.6%) 1
Female gender 56 (52.83%) 12 (54.5%) 44 (52.4%) 1
Hight [cm] 170.13 ± 8.63 (152–200) 170.64 ± 8.56 (158–190) 170.00 ± 8.697 (152–200) 0.734
Hight male [cm] 175.06 ± 8.58 (156–200) 175.60 ± 9.13 (158–190) 174.93 ± 8.56 (156–200) 0.658
Hight female [cm] 165.73 ± 5.90 (152–184) 166.50 ± 5.54 (158–176) 165.52 ± 6.04 (152–184) 0.581
BMI > 30 kg/m² 22 (20.8%) 11 (50.0%) 11 (13.1%) < 0.001
BMI [kg/m2] 26.39 ± 5196 (17.3–42.1) 30.03 ± 5.21 (22.4–40.5) 25.43 ± 4.78 (17.3–42.1) < 0.001
BMI male [kg/m2] 28.03 ± 5.23 (19.5–42.1) 30.66 ± 4.87 (22.4–37.7) 27.37 ± 5.17 (19.5–42.1) 0.056
BMI female [kg/m2] 24.92 ± 4.747 (17.3–40.5) 29.51 ± 5.63 (23.1–40.5) 23.67 ± 3.64 (17.3–34.1) 0.001
Cardiologic work-up
Clinical examination 106 (100%) 22 (100%) 84 (100%) 1
Holter ECG 83 (78.3%) 17 (81.0%) 66 (80.5%) 1
Echocardiography 106 (100%) 22 (100%) 84 (100%) 1
Stress echocardiography 10 (9.6%) 3 (14.3%) 7 (8.4%) 0.418
Ergometry 34 (32.1%) 7 (33.3%) 27 (32.5%) 1
Coronary angiography 91 (85.8%) 21 (95.5%) 70 (83.3%) 0.067
Electrophysiology testing 38 (35.8%) 9 (42.9%) 29 (34.9%) 0.613
Laboratory findings before ILR implantation
Creatinin [mg/dL] 1.003 ± 0.72 (0.54–7.54) 1.07 ± 0.49 (0.64–2.41) 0.99 ± 0.77 (0.54–7.54) 0.357
GFR [mL/min] 77.58 ± 22.18 (6.84–133.68) 71.456 ± 26.81 (23.95–133.68) 79.18 ± 20.69 (6.84–133.01) 0.134
GFR < 60 mL/min 21 (19.8%) 10 (45.5%) 11 (13.1%) 0.002
Hb [g/dL] 13.70 ± 1.31 (9.2–17.5) 13.60 ± 1.28 (11.3–15.7) 13.73 ± 1.322 (9.2–17.5) 0.562
TSH [mU/L] 1.49 ± 1.03 (0.01–6.52) 1.82 ± 1.41 (0.57–6.52) 1.41 ± 0.92 (0.01–4.64) 0.24
Potassium [mmol/L] 4.045 ± 0.37 (3.1–5.9) 4.047 ± 0.307 (3.4–4.6) 4.045 ± 0.38 (3.1–5.9) 0.669
ECG characteristics
Right bundle branch block 8 (7.7%) 5 (23.8%) 3 (3.6%) 0.008
Left bundle branch block 4 (3.8%) 0 4 (4.8%) 1
Left anterior hemiblock 6 (5.8%) 1 (4.8%) 5 (6.0%) 0.580
Left posterior hemiblock 0 0 0 –
Intraventricular conduction 
delay
0 0 2 (2.4%) 1
Any bundle branch block 20 (18.9%) 6 (27.3%) 14 (16.7%) 0.229
First degree AVB 11 (10.6%) 2 (9.5%) 9 (10.8%) 1
Heart rate [bpm] 70.70 ± 15.24 (38–118) 70.52 ± 14.71 (52–118) 70.747 ± 15.46 (38–118) 0.843
PR interval [ms] 164.47 ± 30.28 (120–268) 169.33 ± 29.53 (124–252) 163.32 ± 30.53 (120–268) 0.322
QRS duration [ms] 95.92 ± 20.697 (60–186) 100.68 ± 18.46 (76–146) 94.80 ± 21.14 (60–186) 0.082
QT duration [ms] 402.11 ± 37.73 (304–510) 411.78 ± 34.14 (336–466) 399.76 ± 38.395 (304–510) 0.158
QTc duration [ms] 423.54 ± 43.81 (98–570) 432.32 ± 25.16 (380–487) 421.48 ± 47.02 (98–570) 0.144
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Table 1B.
Parameter All patients  
(n = 106)
Patients with PM  
(n = 22)
Patients without PM  
(n = 84)
P
Associated cardiovascular and neurological disorders
TIA or stroke 15 (14.2%) 3 (13.6%) 12 (14.3%) 1
Diabetes type II 19 (17.9%) 5 (22.7%) 14 (16.7%) 0.538
Arterial hypertension 67 (63.8%) 19 (86.4%) 48 (57.8%) 0.013
Metabolic syndrome 27 (25.5%) 10 (45,5%) 17 (20,2%) 0.026
Systolic BP [mmHg] 122.88 ± 17.07 (80–170) 126.19 ± 17.99 (80–162) 122.048 ± 16.84 (90–170) 0.137
Diastolic BP [mmHg] 73.47 ± 10.64 (50–100) 77.24 ± 13.74 (55–100) 72.52 ± 9.57 (50–95) 0.121
Congestive heart failure 18 (17.1%) 3 (13.6%) 15 (18.1%) 0.759
Atrial fibrillation 29 (27.6%) 10 (45.5%) 19 (22.9%) 0.058
Coronary heart disease 26 (28.3%) 7 (31.8%) 19 (27.1%) 0.787
Cardiomyopathy (HCM, 
DCM, ARVC)
7 (6.6%) 1 (4.5%) 6 (7.1%) 1
Structural heart disease 47 (44.3%) 11 (50.0%) 36 (42.9%) 0.632
Moderate to severe  
structural heart disease
17 (16.0%) 3 (13.6%) 14 (16.7%) 1.0
LVEF [%] 57.60 ± 6.45 (35–72) 56.59 ± 6.05 (40–65) 57.87 ± 6.55 (35–72) 0.544
LVEF normal 88 (73.6%) 19 (86.3%) 69 (80.1%) 0.567
LVEF slightly reduced 14 (13.2%) 4 (18.2%) 10 (11.9%) 0.482
LVEF moderat reduced 4 (3.8%) 1 (4.5%) 3 (3.6%) 1
LVEF highly reduced 0 0 0 –
Second or higher degree 
valve defect
14 (14.4%) 3 (14.3%) 11 (14.5%) 1
Left ventricular hypertrophy 47 (44.3%) 13 (59.1%) 34 (46.6) 0.339
Septal diameter [mm] 12.17 ± 4.10 (6–32) 12.10 ± 1.83 (9–15) 12.20 ± 4.53 (6–32) 0.321
Concomittant medication
Beta-blocker 58 (54.7%) 16 (72.7%) 42 (50.0%) 0.091
ACEI 36 (34%) 7 (31.8%) 29 (34.5%) 1
AT1-blockers 31 (29.2%) 11 (50.0%) 20 (23.8%) 0.033
Aldosterone antagonist 2 (1.9%) 0 2 (2.4%) 1
Digitalis 1 (0.9%) 0 1 (1.2%) 1
Class III anti-arrhythmic drugs 1 (0.9%) 0 1 (1.2%) 1
Class I anti-arrhythmic drugs 0 0 0 - 
Calcium channel blockers 23 (21.7%) 8 (36,4%) 15 (17.9%) 0.081
Diuretics 33 (31.1%) 10 (45.5%) 23 (27.4%) 0.124
Syncope anamnesis
Additional presyncopes 43 (40.6%) 9 (40.9%) 34 (40.5%) 0.971
1 syncope 17 (16.0%) 2 (9.1%) 15 (17.9%) 0.809
2–3 syncopes 34 (32.1%) 7 (31.81%) 27 (32.1%) 0.809
4–5 syncopes 15 (14.2%) 3 (13.6%) 12 (14.3%) 0.809
> 5 syncopes 40 (37.7%) 9 (40.9%) 31 (36.9%) 0.809
Trauma during syncope 46 (56.8%) 8 (50,0%) 38 (58.5%) 0.583
Family history of syncopes 13 (15.7%) 2 (11,1%) 11 (16.9%) 0.724
Family history of unexplained 
sudden death
12 (13.6%) 1 (5,6%) 11 (15.7%) 0.446
Prodromal symptoms 64 (64.0%) 13 (61.9%) 51 (64.6%) 0.804
Diziness 39 (39.0%) 9 (42.9%) 30 (38.0%) 0.802
Nausea 14 (14.0%) 3 (14.3%) 11 (13.9%) 1
Emesis 1 (1.0%) 0 (0.0%) 1 (1.3%) 1
Impaired vision 11 (11.0%) 3 (14.3%) 8 (10.1%) 0.695
Perspiration 13 (13.0%) 1 (4.8%) 12 (15.2%) 0.290
Sensation of cold 0 0 0 –
Palpipation 19 (17.9%) 3 (14.3%) 16 (20.3%) 0.536
Data are presented as number (percentage) or mean ± standard deviation (range). ACEI — angiotensin-converting enzyme inhibitor;  
ARVC — arrhy-thmogenic right ventricular cardiomyopathy; AT1-blockers — angiotensin II receptor antagonists; AVB — atrioventricular 
block; BMI — body mass index; BP — blood pressure; DCM — dilated cardiomyopathy; ECG — electrocardiogram; GFR — glomerular filtra-
tion rate; Hb — hemoglobin; HCM — hypertrophic cardiomyopathy; LVEF — left ventricular ejection fraction; TIA — transient ischemic attack; 
TSH — thyroid-stimulating hormone; PM — pacemaker
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guidelines for cardiac pacing and cardiac resyn-
chronization therapy [11, 14] in the following 
cases: 1) Patients with symptoms which can clearly 
be attributed to ILR documented bradycardia. 
Symptoms included syncope, presyncope, dizzi-
ness, angina pectoris and dyspnoe. 2) Patients 
with a documented bradycardia during a possible 
reflex syncope and pauses due to sinus arrest or 
atrioventricular block (AV block) longer than 6 s. 
3) Patients with a relevant but asymptomatic 
bradycardia documented by ILR. Following brad-
yarrhythmias were considered significant even in 
the absence of symptoms: Sinus arrest due to sinus 
dysfunction with pauses ≥ 3 s with an exception 
of young trained persons, during sleep and when 
bradycardia is induced by concomitant drugs; Mo-
bitz II second-degree AV block or third-degree AV 
block, AF with slow ventricular conduction leading 
to intermittent pauses of at least 3 s during day 
time without reversible cause. 
Statistical analysis
Mean values ± standard deviation (SD) and 
range were reported to describe continuous vari-
ables. Percentages were presented to report cat-
egorical variables. For univariate testing differ-
ences between PM and non-PM implantation 
patients were analyzed by Mann-Whitney U-test 
for non-normally distributed variables. Categorical 
variables were compared using the Fisher exact 
test. Thereafter a multivariate stepwise logistic 
regression analysis was performed to identify 
clinical predictors of PM implantation. Univariate 
and multivariate analyses were adjusted by age and 
gender. Kaplan–Meier survival curves were used 
to present time course to syncopal recurrence and 
to occurrence of bradyarrhythmia. All p-values are 
two-sided, and a p-value of < 0.05 was considered 
to be statistically significant. All analyses were 
performed using SPSS® for Windows Version 22.0 
(SPSS Inc.).
Results
Patient population
Between February 2009 and August 2014 a total 
of 106 patients (age 59.1 ± 17.5; 50 [47.2%] male) 
met the inclusion criteria of this study. Demograph-
ic characteristics and comorbidities of the study 
population group are shown in Tables 1A and 1B. 
Amongst the study population, Holter monitoring 
(24 h to 5 days) was done in 83 (78.3%) patients. 
Coronary angiography was performed in 91 (85.8%) 
patients to exclude coronary artery disease. Stress 
echocardiography was performed in 10 (9.6%) and 
ergometry in 34 (32.1%) patients. There were 38 
(35.8%) patients who had electrophysiology testing 
performed prior to ILR insertion. The majority of 
patients (88; 73.6%) had  normal LVEF, 14 (13.2%) 
patients had  slightly reduced LVEF and only 
4 (3.8%) patients had moderately reduced LVEF. 
Forty-six (56.8%) patients had a trauma secondary 
to syncope. Eighty-nine (83.7%) patients experi-
enced two or more syncopal episodes prior to ILR 
insertion. Twelve (13.6%) patients had a family his-
tory of sudden cardiac death. Atrial fibrillation was 
known before ILR implantation in 29 (27.6%) pa-
tients. The mean PR interval was 164.6 ± 30.3 ms 
with no significant difference (p = 0.322) be- 
tween the group receiving a PM (169.3 ± 29.5 ms) 
and the group not receiving a PM (169.3 ± 30.5 ms). 
Mean heart rate (HR) at ILR implantation was 
70.7 ± 15.2 bpm. All patient characteristics used 
for univariate analyses are depicted in Tables 
1A and 1B.
Follow-up. Data and study endpoints
Details on patient follow-up are depicted in 
Figure 1. Mean follow-up in this study population 
was 19.8 ± 15.4 (0.1–58.8) months. No death 
was recorded in the study population during the 
follow-up period. Overall,  diagnosis is based on 
the ILR was made in 46 (43.4%) patients. The most 
common diagnosis was non-arrhythmic syncope 
(19 patients). In 22 (20.8%) patients a PM was 
implanted due to documented bradyarrhythmic 
episodes, of whom 10 (45.5%) patients were male 
(age 62.2 ± 12.7 years). The median time from ILR 
insertion to documented bradycardia and consecu-
tive PM implantation was 81 ± 88 (range 2 to 350) 
days. Ten (45.5%) patients had a PM implanted for 
sinus arrest, 2 (9.1%) patients had a second-degree 
AV block, 7 (31.8%) patients showed third-degree 
AV block and 1 (4.5%) patient had AF with a slow 
ventricular rate. In 10 (45.5%) patients a PM 
was implanted due to syncope recurrence with 
documented significant bradyarrhythmic epi-
sodes, whereas in 12 (54.5%) patients significant 
bradycardia was considered an indication for PM 
implantation even in the absence of symptoms. Two 
(9.1%) patients suffered from a recurrent syncope 
after PM implantation. 
In 5 (4.7%) patients, new tachyarrhythmic epi-
sodes were found during ILR monitoring. In 3 (2.8%) 
of these patients paroxysmal supra ventricular tach-
ycardia (AV-nodal reentry tachycardia, atrial flut-
ter) was recorded, which was successfully treated 
by catheter ablation. In 1 patient a paroxysmal 
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supraventricular tachycardia was associated with 
syncope recurrence. Two (1.9%) patients under-
went implantable cardioverter-defibrillator (ICD) 
implantation because of documented ventricular 
tachycardia. In 4 (3.8%) patients an oral antico-
agulation therapy was initiated due to first time 
detection of AF or atrial flutter. Figure 2 depicts 
the time course of diagnosis, either exclusion of an 
arrhythmogenic cause due to syncopal recurrence 
without documented rhythm disorders (Fig. 2A) 
or documentation of relevant bradyarrhythmic 
events necessitationg PM implantation (Fig. 2B).
Clinical predictors of PM implantation
In the univariate analyses, (Table 2) the follow-
ing factors were associated with PM implantation 
after additional adjustment for gender and age: 
obesity, defined by a body mass index (BMI) above 
30 kg/m² (odds ratio [OR]: 8.096; 95% confidence 
interval [CI] 2.619–25.023; p < 0.001), renal fail-
ure with a glomerular filtration rate (GFR) of less 
than 60 mL/min calculated using the Cockcroft-
Gault formula (OR: 6.147; 95% CI 1.857–20.352; 
p = 0.003), a right bundle branch block (RBBB) 
(OR: 8.058; 95% CI 1.740–37.327; p = 0.008), 
arterial hypertension (OR: 6.255; 95% CI 1.332– 
–29.378; p = 0.020), medical treatment with 
AT1-receptor blockers (OR: 3.254; 95% CI 
1.085–9.753; p = 0.035) and the metabolic syndrome 
(OR: 3.262; 95% CI 1.147–9.275; p = 0.027). 
Variables which were significant predictors 
of PM implantation in univariate analysis were 
further analyzed by a multivariate regression 
analysis. From six factors which were determined 
by multivariate regression analysis, the following 
factors were identified as independent predictive 
factors of PM implantation (Table 2): Obesity, de-
fined by a BMI above 30 kg/m² (OR: 7.388; 95% 
CI 1.495–36.506; p = 0.014), a RBBB (OR: 9.401; 
95% CI 1.357–65.117; p = 0.023) and renal failure 
with a GFR of less than 60 mL/min [2] (OR: 6.420; 
95% CI 1.156–35.655; p = 0.035). 
The rate of PM implantation according to the 
presence of risk factor in the present study popula-
tion is displayed in Figure 3. A combination of two 
or more predictors significantly increased the rate 
of PM implantation.
Discussion
The current study aimed to identify clinical 
predictors of bradycardia necessitating PM implan-
tation in patients with unexplained syncope during 
ILR monitoring. In the present study, bradycardia 
Figure 1. Follow-up data of the overall study population after implantable loop recorder (ILR) implantation; AF — atrial 
fibrillation; AVB — atrioventricular block; ICD — implantable cardioverter-defibrillator; PM — pacemaker; SVT — 
supraventricular tachycardia; VT — ventricular tachycardia.
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requiring PM implantation was found in 22 out of 
106 patients (20.8%). This proportion is compara-
ble to previous published data (14–21%) [9, 15]. 
The overall diagnosis rate was higher than reported 
by others (43.4%), whereas data from large regis-
tries reveal a final diagnosis in approximately 30% 
of the patients [9, 12, 13, 15].
Obesity, chronic renal failure with a GFR < 60 
mL/min and RBBB were identified as significant 
independent clinical predictors of PM implanta-
tion. In addition, the existence of two or more 
predictors significantly increased the rate of PM 
implantations. All three identified risk factors are 
possible markers for an underlying medical condi-
tion that may be associated with an impairment of 
the electrical impulse generating and conduction 
system of the heart.
Chronic renal failure
A negative impact of chronic kidney disease 
(CKD) on cardiac function and alterations of cardiac 
rhythm stability has been known for a long time. 
The cardiorenal syndrome refers to the intercon-
nection of heart and kidney dysfunctions and is 
related to poor clinical outcomes [16]. Chronic 
kidney disease has been shown to be a risk factor 
of sudden cardiac death caused by cardiomyopa-
thy, myocardial inflammation, myocardial fibrosis, 
arrhythmias and conduction abnormalities [17, 
18]. Sudden cardiac death in patients with chronic 
renal failure is associated with increased levels 
of inflammatory markers such as high-sensitivity 
C-reactive protein and interleukin 6 which are both 
linked to fibrotic changes of the myocardium and 
the electrical conduction system itself [19]. Previ-
Table 2. Predictors of pacemaker implantation in the overall study population according to odds ratio (OR) 
calculated by univariate and multivariate analysis. 
Variable Univariate analysis* Multivariate analysis
OR 95% CI p OR 95% CI p
BMI > 30 kg/m2 8.096 2.619–25.023 < 0.001 7.388 1.495–36.506 0.014
GFR < 60 mL/min 6.147 1.857–20.352 0.003 6.42 1.156–35.655 0.035
Right bundle branch block 8.058 1.740–37.327 0.008 9.401 1.357–65.117 0.023
Arterial hypertension 6.255 1.332–29.378 0.02 4.064 0.611–27.041 0.147
AT1-blockers 3.254 1.085–9.753 0.035 1.05 0.205–5.380 0.954
Metabolic syndrome 3.262 1.147–9.275 0.027 0.43 0.078–2.358 0.331
*Adjusted for age and sex; BMI — body mass index; CI — confidence interval; GFR — glomerular filtration rate
Figure 2. Time course after implantable loop recorder (ILR) insertion of exclusion of an arrrhythmogenic cause due 
to syncopal recurrence without documented rhythm disorders (A) and time course of documented relevant brady-
arrhythmia necessitating pacemaker implantation (B). 
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ous studies reported that CKD is independently 
associated with alterations in left atrial function 
(left atrial volume and atrial strain rate) as well as 
ventricular strain rates, both markers for myocar-
dial fibrosis [20, 21]. Accordingly, cMRI studies 
revealed myocardial fibrotic alterations in patients 
with CKD [22]. Based on these alterations in myo-
cardial interstitial structure chronic changes in 
sinus node function and cardiac conduction system 
are reasonable [23, 24]. However, renal failure has 
not been identified as an independent risk factor 
for bradyarrhythmic events as yet. In the present 
study a highly significant association between PM 
implantation and bradyarrhythmic event in patients 
with a GFR of less than 60 mL/min was found, this 
measurement is defined as cutoff for a CKD stage 3.
Obesity and metabolic syndrome
Several studies have demonstrated an asso-
ciation between obesity and cardiac arrhythmias 
with increased risk of sudden cardiac death and 
AF [25, 26]. Obesity is associated with pathological 
myocardial changes such as myocyte hypertrophy, 
fibrosis, focal myocardial disarray, fatty infiltration, 
and increased epicardial fat [27]. The effect of 
myocardial fibrosis on sinus node function and the 
electrical conduction system has been described 
previously [28]. Thus, previous animal studies 
have shown that metabolic syndrome and obesity 
induce alterations of sinus node function due to 
fat accumulation around nodal cardiomyocytes 
and changes in sympathetic innervation [29, 30]. 
Moreover, obesity associated increased leptin and 
reduced adiponectin levels might also contribute 
to increased atrial fibrosis [31]. Amongst the pre-
sent study population 10 (9.4%) patients had PM 
implanted due to sinus arrest.
Long-term effects of myocardial fibrosis on the 
electrical conduction systems have been described 
in the context of various cardiac diseases. Thus, 
functional alterations in the AV-node associated 
with increased fibrosis were reported in animal 
models of heart failure [32]. In a large-scale Aus-
tralian cohort study the risk of hospitalization with 
a primary diagnosis of AV block has been shown 
to significantly increase with an increment of BMI 
[33]. In addition to structural changes as an under-
lying cause of sinus node and electrical conduction 
system dysfunction in obese patients, functional 
alterations associated with sleep apnea have also 
been documented in these patients [34, 35] severe 
sleep apnea is a known risk factor of sudden cardiac 
death. However, the role of bradyarrhythmias in 
patients with severe sleep apnea and a potential 
beneficial effect of PM therapy in patients with 
prolonged episodes of asystole is still controversial 
[35]. Amongst the present study population, sleep 
apnea induced bradycardia is rather unlikely as 
bradyarrhythmic episodes necessitating PM im-
plantation occurred solely during daytime. Among 
this study population 9 (8.5%) patients had PM 
implanted for AV block.
Right bundle branch block
The 2013 ESC guidelines on cardiac pacing 
state that PM implantation may be considered in 
selected patients with unexplained syncope and 
bundle branch block (BBB) (recommendation 
class IIb) [11]. The Bradyarrhythmia detection 
in the BBB (B4) Study analyzed the clinical out-
comes of patients with syncope and BBB followed 
a systematic diagnostic approach, including elec-
trophysiological study and ILR implantation [36]. 
Although the most common cause of syncope in 
these patients was bradyarrhythmia, mostly due 
to paroxysmal AV block, other etiologies of syn-
cope were identified in 17.6% of the study popula-
tion. The PRESS Study, a prospective multicenter 
study randomized 101 patients with bifascicular 
block and unexplained syncope implanted with 
a dual chamber PM to either DDD pacing mode 
with a 60 ppm lower rate or DDI mode with 
30 ppm lower rate [37]. The use of a dual cham-
ber PM programmed to DDD 60 ppm led to 
Figure 3. Risk of pacemaker implantation in the overall 
study population according to the number of independ-
ent predictive risk factors. A combination of two or 
more predictors significantly increased the risk of pace-
maker implantation. 
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a significant reduction of the combination of 
syncope/presyncope compared with DDI 30 ppm 
programming [37]. The composite primary end 
point occurred in 23 patients, whereas only 14 
patients developed a class I indication for per-
manent pacing during the course of the study. In 
addition, several studies focusing on the outcome 
of patients with bifascicular block and previous 
syncope reported consistent rates of AV block 
development over time [38]. However, none of 
these studies was designed to identify clinical pre-
dictors of bradyarrhythmic events necessitating 
PM implantation. In the present group of syncopal 
patients, the incidence of left bundle branch block 
(LBBB) was relatively low, which might explain 
why statistical significance was not achieved in 
this subgroup. Moreover, in elderly patients with 
LBBB and unexplained syncope, PM implantation 
was often the therapy of choice in the present 
institution instead of ILR implantation.
Comparison of previous studies evaluating 
predictors of PM implantation 
Several studies analyzed the effectiveness 
of ILRs or prolonged monitoring in predicting 
the cause of syncope, reporting a diagnostic yield 
up to 78% [9, 39–41]. However, only few studies 
were specifically designed to identify clinical pre-
dictors of bradycardia requiring PM implantation 
in patients with unexplained syncope undergoing 
ILR monitoring. Previous work by Palmisano et 
al. [12] identified age > 75 years, a history of 
trauma secondary to syncope and asymptomatic 
bradycardia as independent predictive factors for 
bradyarrhythmias necessitating PM implantation 
in patients receiving an ILR due to unexplained 
syncope. In addition, Ahmed et al. [13] recently 
found that age > 75 years, female sex, a history 
of injury secondary to syncope and a prolongation 
of the PR interval over 200 ms are independent 
predictors of PM implantation in these patients.
Differences between the present results and 
previous studies are probably related to the rela-
tively small cohort of patients and high heterogene-
ity. Thus, the present study and work by Palmisano 
et al. [12] and Ahmed et al. [13] differs in terms of 
patient characteristics, clinical work-up preceding 
ILR implantation, cohort size, type and program-
ming of implanted ILRs. Palmisano et al. [12] 
enrolled 56 patients with a mean age of 68.1 years 
(61% male), whereas our study population included 
106 patients with a mean age of 59.1 years (50% 
male). Thus, the rates of PM implants were also 
analyzed in this study cohort in patients < 75 years 
vs. patients ≥ 75 years and no statistically signifi-
cant difference was found. A possible explanation 
for this finding might be that older patients were 
treated with syncope and particularly those with 
subsequent traumatic injury and a lower threshold 
for implanting a PM instead of considering ILR 
monitoring.
In the study population of Palmisano et al. 
[12] only 11 patients had bradyarrhythmic events 
necessitating PM implantation, which may have led 
to an overinterpretation of the validity in identified 
predictive factors. The study population of Ahmed 
et al. [13] consisted of 200 patients with a mean age 
of 61.7 years (45% male). However, compared to 
Ahmed et al. [13] the frequency of hypertension, 
diabetes and coronary artery disease in the present 
study population was higher and the incidence of 
RBBB and LBBB was lower.
Clinical impact
As previous studies have shown that recurrent 
syncope increases both mortality and morbidity 
[42], early diagnosis and timely therapeutic inter-
vention is essential in patients presenting with 
unexplained syncope. ILRs have been shown to 
be a useful and cost-effective tool in the diagnosis 
for patients with unexplained syncope [41, 43, 
44], however this method has the drawback of 
a prolonged period of observation with possible 
syncopal recurrences before diagnosis and thera-
peutic intervention.
As a cardiac cause of syncope was established 
in 22.4% of syncopal patients with ILR (128 out 
of 570) in the PICTURE (Place of Reveal in the 
Care pathway and Treatment of patients with 
unexplained Recurrent Syncope) registry [9], in 
identification of predictors of arrhythmic syncope, 
it is important to identify patients at higher risk of 
developing future bradyarrhythmic events. A risk 
stratification for patients with unexplained syncope 
based on predictive factors which can easily be 
assessed during the initial work-up might help to 
identify patients necessitating PM implantation and 
thereby expedite timely device therapy.
Limitations of the study
The study presented here has two main limita-
tions. First, it is retrospective single center analy-
sis of a relatively small cohort of patients. Second, 
overall RBBB was documented in only 8 (7.7%) 
patients. Thus, despite the statistical significance 
the relatively small number of patients with RBBB 
may have introduced bias in to the interpretation 
of the results.
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Conclusions
The present study identified patients in 
a population receiving ILR due to unexplained syn-
cope obesity, RBBB and chronic renal failure with 
a GFR < 60 mL/min as independent predictors of 
future bradyarrhythmic events requiring PM im-
plantation. Moreover, a combination of two or more 
of these predictive factors significantly increased 
the risk of PM implantation. Thus, PM implanta-
tion might be directly considered in patients if all 
identified predictive factors are present to reduce 
mortality and morbidity associated with recurrent 
syncope. However, a large prospective, multicenter 
study is necessary to corroborate these findings.
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